Values of plasma homocysteine in patients over 65 years in a third level health institution of Mexico City
Keywords:
Homocysteine, elderly population, tertiary care, Mexico, hyperhomocysteinemiaAbstract
Objective: To determine the levels of homocysteine (Hcy) in older adults and the possible association with the studied variables. Methodology: Cross-sectional, descriptive and exploratory design; both sexes,> 65 years. Sociodemographic and clinical characteristics were evaluated; 5 mL of blood were extracted; classification used for Hcy: Normal 5-14, μmol/L 15-29 slight, ≥ 30 high. Plasma quantitation by HPLC. Patients were grouped according to these determinations. Descriptive statistics, normality testing of Kolmogorov-Smirnov, χ2 categorical variables, unilateral ANOVA, multiple linear regression model: predictive variables (sociodemographic and clinical characteristics), dependent variable (Hcy levels). Significance level of p <0.05. Results: N = 149, age 76.6 ± 7.2, 65% women,> 85 years, widows 68.2% (p = 0.003). Media Hcy, women 22.3 ± 11.8, men 23.4 ± 11.9; General 22.7. Hcy concentration was different in all age groups; the most frequent level of this metabolite was 15-29 μmol/L with p = 0.001. In one-way ANOVA we found no differences among the three groups, weight (p = 0.001), BMI (p = 0.027), age (p = 0.054) and hypertension (p = 0.040). The predictor variables in the model were age: p = 0.002; BMI p = 0.030; osteoporosis p = 0.001 and fractures p = 0.022; dyslipidemia p = 0.088. In this first study that determines the levels of Hcy and sets the frequency by age in older adults, most of them showed elevated levels of Hcy, suggesting that it is a risk factor for the diseases studied. Is necessary to make future epidemiological studies to establish
References
Córdoba A, Blanco F, González F. Bases moleculares de la hiperhomocisteinemia. Quim Clin. 1998; 17 (1): 5-18.
Bjørke MA, Ueland PM. Homocysteine and methylma- lonic in diagnosis and risk assessment from infancy to adolescent. Am J Clin Nutr. 2003; 78 (1): 7-21.
Kian T, Zavaleta M, Romero B. Valores referenciales de homocisteína plasmática en adultos aparentemen- te sanos de Lima-Perú. Diagnóstico (Internet). 2002 citado 14 Abril 2002; 41 (1). Disponible en: http://www. fihu-diagnostico. org.pe/revista/numeros/2002/ene- feb02/28-36
Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B. The natural history of homocystinuria due to cysta- thionine beta-synthase deficiency. Am J Hum Genet. 1985; 37 (1): 1-31.
Moghadasian MH, McManus BM, Frohlich JJ. Homo- cystine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med. 1997; 157 (20): 2299-2308.
Rivara ML, Di Genaro G, González RD. Homocisteína y enfermedad vascular oclusiva. Revista de Posgrado de la VIa Cátedra de Medicina. 2006; 154: 24-30.
Refsum H, Ueland PM, Nygård O, Vollset SE. Homo- cysteine and cardiovascular disease. Annu Rev Med. 1998; 49: 31-62.
Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996; 27 (3): 517-527.
Córdoba A, Blanco F, González F. Hiperhomocisteine-
mia, un nuevo marcador de riesgo vascular. Med Clin
(Barc). 1997; 109: 715-725.
Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993; 270 (22): 2693-2698.
Vangelder E, Delecourt F, Cardozo MB, Dhondt JL, Forzy G. Hyperhomocysteinaemia and type 2 diabetes. Ann Biol Clin (Paris). 2006; 64 (5): 485-489.
Setola E, Monti LD, Galluccio E, Palloshi A, Fragasso G, Paroni R et al. Insulin resistance and endotelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. Eur J Endo- crinol. 2004; 151 (4): 483-489.
Religa D, Czyzewski K, Styczynska M, Peplonska B, Lokk J, Chodakowska ZM et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson’s disease. Neurosci Lett. 2006; 404 (1-2): 56-60.
McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006; 354 (26): 2764-2772.
Malinow MR, Kang SS, Taylor LM, Wong PW, Coull B. Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation. 1989; 79 (6): 1180-1188.
Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants
of plasma levels in middle-aged and elderly subjects. J
Intern Med. 1994; 236 (6): 633-641.
Vrentzos GE, Papadakis JA, Vardakis KE, Maliaraki N,
Stilianou K. Intravenous administration of vitamin B12 in the treatment of hyperhomocysteinemia associated with end-stage renal disease. J Nephrol. 2003; 16 (4): 535-539.
Seshadri N, Robinson K. Homocisteína, vitaminas B, y arteriopatía coronaria. Medical Clinics of North America. 2000; 84: 219-241.
Martin SC, Tsakas-Ampatzis I, Bartlett WA, Jones AF. Measurement of plasma total homocysteine by HPLC with coulometric detection. Clin Chem. 1999; 45 (1): 150-152.
Diario Oficial de la Federación. Manejo integral de la Obesidad. Norma Oficial Mexicana NOM-174- SSA1-1998: 3-4.
Bray G, Bouchard C, James WPT. Definitions and proponed current classifications of obesity Handbook of obesity, Vol. 2, 4th ed. New York: Marcel Dekker, 1998. pp. 53-75.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which allows to reproduce and modify the content if appropiate recognition to the original source is given.
